Co-Authors
This is a "connection" page, showing publications co-authored by Elbert Huang and Wen Wan.
Connection Strength
3.578
-
The Economic Evaluation of Team Clinic-Group Approach to a Care Model of Early Adolescents With Type 1 Diabetes. J Pediatr Health Care. 2022 Sep-Oct; 36(5):430-437.
Score: 0.883
-
Cost-effectiveness of Shared Telemedicine Appointments in Young Adults With T1D: CoYoT1 Trial. Diabetes Care. 2019 08; 42(8):1589-1592.
Score: 0.713
-
Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial. Med Decis Making. 2018 11; 38(8):942-953.
Score: 0.684
-
Cost-effectiveness of Continuous Glucose Monitoring for Adults With Type 1 Diabetes Compared With Self-Monitoring of Blood Glucose: The DIAMOND Randomized Trial. Diabetes Care. 2018 06; 41(6):1227-1234.
Score: 0.658
-
Costs and Health Care Utilization Analysis of Medical Group Visits for Adults With Type 2 Diabetes in Community Health Centers. Med Care. 2023 12 01; 61(12):866-871.
Score: 0.241
-
Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults. MDM Policy Pract. 2023 Jul-Dec; 8(2):23814683231187566.
Score: 0.237
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
Score: 0.056
-
Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis. J Gen Intern Med. 2022 02; 37(2):439-448.
Score: 0.053
-
The Longer-Term Benefits and Harms of Glucagon-Like Peptide-1 Receptor Agonists: a Systematic Review and Meta-Analysis. J Gen Intern Med. 2022 02; 37(2):415-438.
Score: 0.052